1154 related articles for article (PubMed ID: 32436290)
21. Sublingual allergen immunotherapy: immunological mechanisms and prospects for refined vaccine preparation.
O'Hehir RE; Sandrini A; Anderson GP; Rolland JM
Curr Med Chem; 2007; 14(21):2235-44. PubMed ID: 17896972
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
23. Maintenance-Phase Subcutaneous Immunotherapy with House Dust Mites Induces Cyclic Immunologic Effects.
Chaoul N; Albanesi M; Giliberti L; Rossi MP; Nettis E; Di Bona D; Caiaffa MF; Macchia L
Int Arch Allergy Immunol; 2019; 179(1):37-42. PubMed ID: 30921804
[TBL] [Abstract][Full Text] [Related]
24. Impact of allergen immunotherapy in allergic asthma.
Zhang W; Lin C; Sampath V; Nadeau K
Immunotherapy; 2018 Jun; 10(7):579-593. PubMed ID: 29569506
[TBL] [Abstract][Full Text] [Related]
25. Dose dependence of efficacy but not of safety in sublingual immunotherapy.
Frati F; Incorvaia C; Marcucci F; Sensi L; Di Cara G; Puccinelli P; Dal Bo S
Monaldi Arch Chest Dis; 2006 Mar; 65(1):38-40. PubMed ID: 16700192
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of Subcutaneous and Sublingual Aeroallergen Immunotherapy: What Is New?
Komlósi ZI; Kovács N; Sokolowska M; van de Veen W; Akdis M; Akdis CA
Immunol Allergy Clin North Am; 2020 Feb; 40(1):1-14. PubMed ID: 31761112
[TBL] [Abstract][Full Text] [Related]
27. Allergen-specific immunotherapy.
Nelson HS; Norman PS
Chem Immunol Allergy; 2014; 100():333-8. PubMed ID: 24925414
[TBL] [Abstract][Full Text] [Related]
28. Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children.
Pelaia C; Vatrella A; Lombardo N; Terracciano R; Navalesi P; Savino R; Pelaia G
Expert Opin Biol Ther; 2018 Feb; 18(2):197-204. PubMed ID: 29113525
[TBL] [Abstract][Full Text] [Related]
29. Progress in the development of specific immunotherapies for house dust mite allergies.
Moingeon P
Expert Rev Vaccines; 2014 Dec; 13(12):1463-73. PubMed ID: 25187166
[TBL] [Abstract][Full Text] [Related]
30. [Update on current care guidelines: Allergen specific immunotherapy].
Valovirta E; Korhonen K; Kuitunen M; Kukkonen-Harjula K; Lammintausta K; Pallasaho P; Ralli P; Savolainen J; Toskala E; Virtanen T
Duodecim; 2012; 128(1):108-9. PubMed ID: 22312833
[TBL] [Abstract][Full Text] [Related]
31. An immunological overview of allergen specific immunotherapy -- subcutaneous and sublingual routes.
Ozdemir C
Ther Adv Respir Dis; 2009 Oct; 3(5):253-62. PubMed ID: 19880430
[TBL] [Abstract][Full Text] [Related]
32. Treatment of respiratory allergy with allergy immunotherapy tablets.
Bachert C
Allergy; 2011 Jul; 66 Suppl 95():57-9. PubMed ID: 21668858
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in immunotherapy for allergic diseases.
El-Qutob D; Mencia G; Fernandez-Caldas E
Recent Pat Inflamm Allergy Drug Discov; 2014 Jan; 8(1):24-35. PubMed ID: 24237114
[TBL] [Abstract][Full Text] [Related]
34. Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy.
Boonpiyathad T; Sokolowska M; Morita H; Rückert B; Kast JI; Wawrzyniak M; Sangasapaviliya A; Pradubpongsa P; Fuengthong R; Thantiworasit P; Sirivichayakul S; Kwok WW; Ruxrungtham K; Akdis M; Akdis CA
Allergy; 2019 May; 74(5):976-985. PubMed ID: 30485456
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
Canonica GW; Virchow JC; Zieglmayer P; Ljørring C; Smith IM; Mosbech H
Expert Rev Clin Immunol; 2016 Aug; 12(8):805-15. PubMed ID: 27322777
[TBL] [Abstract][Full Text] [Related]
36. Principles of Allergen Immunotherapy and Its Clinical Application in China: Contrasts and Comparisons with the USA.
Guan K; Liu B; Wang M; Li Z; Chang C; Cui L; Wang RQ; Wen LP; Leung PSC; Wei JF; Sun JL
Clin Rev Allergy Immunol; 2019 Aug; 57(1):128-143. PubMed ID: 31243705
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy and safety of subcutaneous versus sublingual immunotherapy.
Bauer CS; Rank MA
J Allergy Clin Immunol; 2014 Sep; 134(3):765-765.e2. PubMed ID: 25171871
[No Abstract] [Full Text] [Related]
38. EAACI guidelines on allergen immunotherapy: Prevention of allergy.
Halken S; Larenas-Linnemann D; Roberts G; Calderón MA; Angier E; Pfaar O; Ryan D; Agache I; Ansotegui IJ; Arasi S; Du Toit G; Fernandez-Rivas M; Geerth van Wijk R; Jutel M; Kleine-Tebbe J; Lau S; Matricardi PM; Pajno GB; Papadopoulos NG; Penagos M; Santos AF; Sturm GJ; Timmermans F; van Ree R; Varga EM; Wahn U; Kristiansen M; Dhami S; Sheikh A; Muraro A
Pediatr Allergy Immunol; 2017 Dec; 28(8):728-745. PubMed ID: 28902467
[TBL] [Abstract][Full Text] [Related]
39. Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report.
Pajno GB; Bernardini R; Peroni D; Arasi S; Martelli A; Landi M; Passalacqua G; Muraro A; La Grutta S; Fiocchi A; Indinnimeo L; Caffarelli C; Calamelli E; Comberiati P; Duse M;
Ital J Pediatr; 2017 Jan; 43(1):13. PubMed ID: 28257631
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
